Jade Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
| · · · · · · · | |||||
|---|---|---|---|---|---|
| · · Year Ended December 31, · | |||||
| · 2024 · 2023 | |||||
| Operating expenses: · · · | |||||
| Research and development | | $53,187 | | $64,219 | |
| General and administrative | | 21,409 | | 17,190 | |
| Total operating expenses | | 74,596 | | 81,409 | |
| Loss from operations | | (74,596) | | (81,409) | |
| Other income (expense): | | | | ||
| Interest income | | 5,042 | | 5,945 | |
| Other expense: | | (19) | | (1) | |
| Total other income | | 5,023 | | 5,944 | |
| Net loss before income taxes | | (69,573) | | (75,465) | |
| Provision for income taxes | | 55 | | 56 | |
| Net loss | | $(69,628) | | $(75,521) | |
| Comprehensive loss: | | | | ||
| Net loss | | $(69,628) | | $(75,521) | |
| Other comprehensive loss: | | | | ||
| Unrealized (loss) gain on securities | | (132) | | 703 | |
| Comprehensive loss | | $(69,760) | | $(74,818) | |
| Net loss per share, basic and diluted | | $(2.44) | | $(2.87) | |
| Weighted-average shares of common stock outstanding, basic and diluted | | 28,582,194 | | 26,331,630 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.